Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Sartorius AG    SRT   DE0007165607

SARTORIUS AG

(SRT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius : Stedim Biotech 2020 Virtual Annual Shareholder´s Meeting | Presentation of the CEO and Chairman of the Board

06/25/2020 | 03:19am EST

Sartorius Stedim Biotech 2020 Virtual AnnualShareholder`s Meeting

Presentation of the CEO and Chairman of the BoardJune 24, 2020

We have coped well with the first phase of the pandemic

Our priorities

  • 1.Safety first: Responsibility for over 6,300 employees

  • 2.Ensure delivery capability for our customers

  • 3.Secure financial stability and strength

Challenges

  • Risks of a second wave of infection, global recession, adaption to longer term changes

  • Remote integration of acquired businesses

2

Our products contribute to the development of effective vaccines

Thank you to our customers for their trust and to all employees and suppliers for keeping our business running!

2019 was another year of dynamic profitable growth

  • Strong 2019 with significant double-digit growth rates-upgraded forecast exceeded

  • Two strategically important acquisitions

  • Position as a leading international technology partner of the biopharma industry expanded

5

Disclaimer

Sartorius AG published this content on 24 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 June 2020 07:18:01 UTC


© Publicnow 2020
All news about SARTORIUS AG
01/15SARTORIUS : Partners With RoosterBio to Advance Cell and Gene Therapy Manufactur..
PU
01/06SARTORIUS : to acquire Novasep's chromatography process equipment...
PU
01/05SARTORIUS STEDIM BIOTECH SA : Bilan SEMESTRIEL S2 -2-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -3-
DJ
01/05SARTORIUS STEDIM BIOTECH SA : Full-year report of -2-
DJ
01/04SARTORIUS VORZUEGE : Receives a Buy rating from JP Morgan
MD
01/04SARTORIUS STEDIM BIOTECH SA : Declaration relative to the number of shares and v..
DJ
2020SARTORIUS : and Evotec Partner With Start-up Curexsys on IPSC-Based...
PU
2020PRESS RELEASE : Evotec and sartorius partner with -2-
DJ
2020SARTORIUS : pays employees a coronavirus bonus
PU
More news
Financials
Sales 2020 2 305 M 2 785 M 2 785 M
Net income 2020 233 M 282 M 282 M
Net Debt 2020 1 759 M 2 125 M 2 125 M
P/E ratio 2020 114x
Yield 2020 0,23%
Capitalization 24 626 M 29 774 M 29 754 M
EV / Sales 2020 11,4x
EV / Sales 2021 9,60x
Nbr of Employees 10 008
Free-Float 46,8%
Chart SARTORIUS AG
Duration : Period :
Sartorius AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SARTORIUS AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 246,58 €
Last Close Price 345,00 €
Spread / Highest target 1,74%
Spread / Average Target -28,5%
Spread / Lowest Target -80,1%
EPS Revisions
Managers and Directors
NameTitle
Joachim Kreuzburg Chief Executive Officer
Lothar Kappich Chairman-Supervisory Board
Volker Niebel Head-Production, Procurement & Business Operations
Rainer Lehmann Chief Financial Officer
Oscar-Werner Reif Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS AG0.00%29 774
REVENIO GROUP OYJ-2.88%1 567
ALPHATEC HOLDINGS, INC.-1.86%1 118
CELLAVISION AB (PUBL)1.24%885
VAREX IMAGING CORPORATION10.67%723
OXFORD IMMUNOTEC GLOBAL PLC25.62%570